No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial.

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. Abstract Text:

de Jong, Jansen,Willibrord Hoefnagels,Marja Jellesma-Eggenkamp,Marcel Verbeek,George Borm,Berry Kremer,

BACKGROUND: The objective of this study was to determine whether treatment with the nonselective nonsteroidal anti-inflammatory drug (NSAID) indomethacin slows cognitive decline in patients with Alzheimer's disease (AD). METHODOLOGY/PRINCIPAL FINDINGS: This double-blind, randomized, placebo-controlled trial was conducted between May 2000 and September 2005 in two hospitals in the Netherlands. 51 patients with mild to moderate AD were enrolled into the study. Patients received 100 mg indomethacin or placebo daily for 12 months. Additionally, all patients received omeprazole. The primary outcome measure was the change from baseline after one year of treatment on the cognitive subscale of the AD Assessment Scale (ADAS-cog). Secondary outcome measures included the Mini-Mental State Examination, the Clinician's Interview Based Impression of Change with caregiver input, the noncognitive subscale of the ADAS, the Neuropsychiatric Inventory, and the Interview for Deterioration in Daily life in Dementia. Considerable recruitment problems of participants were encountered, leading to an underpowered study. In the placebo group, 19 out of 25 patients completed the study, and 19 out of 26 patients in the indomethacin group. The deterioration on the ADAS-cog was less in the indomethacin group (7.8+/-7.6), than in the placebo group (9.3+/-10.0). This difference (1.5 points; CI -4.5-7.5) was not statistically significant, and neither were any of the secondary outcome measures. CONCLUSIONS/SIGNIFICANCE: The results of this study are inconclusive with respect to the hypothesis that indomethacin slows the progression of AD. TRIAL REGISTRATION: ClinicalTrials.gov NCT00432081.

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. Publishing Authors By Initials

D de Jong,R Jansen,W Hoefnagels,M Jellesma-Eggenkamp,M Verbeek,G Borm,B Kremer,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: PLoS ONE

VOLUME: 3

Page Numbers: e1475

Journal Abbreviation: PLoS ONE

ISSN: 1932-6203

DAY: 23

MONTH: 01

YEAR: 2008

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101285081

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial.

AFFILIATION: Department of Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: PLoS ONE

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial Related Publications

• Challenges After Curative Treatment for Childhood Cancer and Long-Term Follow up of Survivors.
• Chloroplast DNA footprints of postglacial recolonization by oaks.
• Determinants of the choice for single or double embryo transfer in twin prone couples.
• Development of a genotyping microarray for Usher syndrome.
• EmbR2, a structural homologue of EmbR, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/EmbR.
• Fokker-Planck-type equations for a simple gas and for a semirelativistic Brownian motion from a relativistic kinetic theory.
• Functional role of the PE domain and immunogenicity of the Mycobacterium tuberculosis triacylglycerol hydrolase LipY.
• Further studies on the utilization of I,3-butanediol as a source of energy in parenteral nutrition.
• Guideline-based development of quality indicators for subfertility care.
• High Mycobacterium bovis genetic diversity in a low prevalence setting.
• Identification of a specific limitation on local-feedback recurrent networks acting as Mealy-Moore machines.
• Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer.
• Kinetics of TmHU binding to DNA as observed by optical tweezers.
• Luetic myocarditis; observations on pathology and problem of establishing a true clinical entity.
• MYO15A (DFNB3) mutations in Turkish hearing loss families and functional modeling of a novel motor domain mutation.
• Mutations of ESRRB Encoding Estrogen-Related Receptor Beta Cause Autosomal-Recessive Nonsyndromic Hearing Impairment DFNB35.
• No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial.
• Sinus CT Scan Findings in "Sinus Headache" Migraineurs.
• Structure-property relationships in major ampullate spider silk as deduced from polarized FTIR spectroscopy.
• Superconductivity in heavy alkaline-Earth intercalated graphites.
• Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria.
• Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
• Treatment of nephrosis with concentrated human serum albumin; effects on the proteins of body fluids.
• [Gynecological cytodiagnosis with screening (a solution from necessity)]
• [HEART DEFECT AND PREGNANCY.]
• [Indications and results of cesarean section 1944-53.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Report of two cases of familial cutaneous and mucosal hyalinosis (lipoid proteinosis).]